 CAMBRIDGE, Mass., Nov. 09, 2021 GLOBE NEWSWIRE -- Jounce Therapeutics, Inc. NASDAQ: JNCE, a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate at the following upcoming investor conferences in November: 